EQS-Ad-hoc: Semperit AG Holding / Key word(s): Miscellaneous Disclosed inside information / Ad hoc release Semperit identifies probable impairment loss in Medical Sector in the order of approximately EUR 50 million
Vienna, Austria, 13 September 2022 – Against the backdrop of the market dynamics for examination and protective gloves, the Executive Board of Semperit AG Holding reviewed the estimates and assumptions relevant to the valuation with regard to the Medical Sector (Sempermed segment). As a result, a probable impairment loss in the order of approximately EUR 50 million as of 30 September 2022 was identified for the segment assets of Sempermed. The exact amount of the impairment loss will be included in the third quarter business development figures and will be disclosed at the latest with the publication of the Q1-3 2022 results on 16 November 2022.
Monika Riedel www.linkedin.com/company/semperit-ag
13-Sep-2022 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
Language: | English |
Company: | Semperit AG Holding |
Am Belvedere 10 | |
1100 Wien | |
Austria | |
Phone: | +43 1 79 777-310 |
Fax: | +43 1 79 777-602 |
E-mail: | judit.helenyi@semperitgroup.com |
Internet: | www.semperitgroup.com |
ISIN: | AT0000785555 |
Listed: | Vienna Stock Exchange (Official Market) |
EQS News ID: | 1441759 |
End of Announcement | EQS News Service |
|
1441759 13-Sep-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.